Paresh KumarPareshKumar

bit.bio in its collaboration and option agreement with BlueRock Therapeutics, a Bayer subsidiary, for the discovery and manufacture of iPSC-derived regulatory T cell therapies.

Moderna in its strategic collaboration with Generation Bio to develop non-viral genetic medicines.

Moderna in its strategic collaboration with Life Edit Therapeutics to accelerate the development of novel in vivo gene editing therapies.

Disc Medicine in its exclusive license agreement with Mabwell Therapeutics for certain rights to a portfolio of TMPRSS6-targeting antibody candidates.

AbCellera in its strategic alliance with Rallybio to discover, develop and commercialize novel antibody-based therapeutics for rare diseases.

Envisagenics in its research collaboration with Bristol Myers Squibb to identify alternative splicing-derived oncology targets.

ProQR Therapeutics in its global licensing and research collaboration with Eli Lilly focused on RNA editing medicines for genetic disorders in the liver and nervous system.

Acadia Pharmaceuticals in its collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for severe and rare neurodevelopmental diseases.

Concert Pharmaceuticals in its sale to BVF Partners and RA Capital Management of an interest in potential future royalties on sales of AVP-786.

Moderna in its strategic research and development collaboration with Metagenomi to develop next-generation in vivo gene editing therapeutics.

Exicure in its exclusive collaboration with Ipsen to research, develop and commercialize novel spherical nucleic acids for rare neurodegenerative disorders.

Trillium Therapeutics in its acquisition by Pfizer.

LEXEO Therapeutics in its acquisition of Stelios Therapeutics and its gene therapy programs for rare cardiovascular diseases.

Moderna in its COVID-19 vaccine supply agreements with governments worldwide.

Represented several biotechnology companies in their companion diagnostic (CDx) agreements with Foundation MedicineRepresented numerous biotechnology companies in IP licensing agreements from leading scientific and medical research institutions around the world